MXCT maxcyte.com: Multiplikator Forward P/S

The development of MaxCyte, Inc. (MXCT) depends on partner investments in cell engineering. The projected P/S ratio helps track such risks, with the 3.60 mark indicating the level of market expectations. MaxCyte, Inc. (MXCT) generates revenue through the sale of Expertita systems and recurring payments for cartridges. Long-term agreements with pharma behemoths ensure a stable cash flow and revenue predictability.

maxcyte.com - Rasio kapitalisasi marang dodolan sing dikarepake MXCT (periode 04.07.2022 - 13.11.2026)

Rincian metrik lan analitis perusahaan MaxCyte Inc (MXCT)

- rega saiki lan proyeksi nilai saham:

Rega saham MaxCyte|MXCT - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar MaxCyte Inc|MXCT - Nilai Bisnis

- statistik nilai buku emiten:

Nilai Buku saben Saham MaxCyte|MXCT - Pambiji Buku Bisnis|Rasio Kapitalisasi Pasar marang Nilai Buku maxcyte.com|MXCT - Gunggung Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian asil keuangan lan kelipatan valuasi:

MXCT - Bathi resik taunan|Bathi mangsa ngarep MaxCyte, Inc.|MXCT - Pangali P/E|Pangali Forward P/E MaxCyte, Inc|MXCT - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan MaxCyte Inc|MXCT - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan MaxCyte|MXCT - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan maxcyte.com|MXCT - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep MaxCyte, Inc.

- indikator volume dodolan lan pendapatan:

MXCT - Volume dodolan perusahaan|Volume dodolan mangsa ngarep perusahaan MaxCyte|MXCT - Kapitalisasi marang volume dodolan|Rasio rega marang prakiraan pendapatan MaxCyte Inc

Ringkesan analitik perusahaan:MaxCyte (MXCT)

To assess the fundamental quality of MaxCyte, Inc. (MXCT), investors must correlate market capitalization with expected revenue adjusted for currency fluctuations. By analyzing the forward P/S ratio, one can filter out market noise and discern the real value of future flows, which is supported by growing demand for electroporation systems within the global genome editing sector and an expanding client base.

Pesaing wigati

Multiplikator Forward P/S ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|GE Healthcare Corp - Multiplikator Forward P/S|MTD (Mettler Toledo Inc) - Kapitalisasi marang prakiraan pendapatan|WAT: Multiplikator Forward P/S|TECH - Rasio kapitalisasi marang dodolan sing dikarepake|BRKR (Bruker) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Azenta Inc (AZTA)|Multiplikator Forward P/S VREX|Multiplikator Forward P/S Semler (SMLR)|Rasio rega marang prakiraan pendapatan Butterfly Network, Inc. BFLY|mesalabs.com - Rasio rega marang prakiraan pendapatan|QSI: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan NNOX (Nano-X Imaging)|QTRX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep 908 Devices Corporation (MASS)|Rasio rega marang prakiraan pendapatan CapsoVision, Inc.|RPID - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan SEER (Seer)|Multiplikator Forward P/S Hyperfine Inc (HYPR)|Multiplikator Forward P/S FONR (FONAR Corp)|Rasio kapitalisasi marang dodolan sing dikarepake Daxor Corp (DXR)|MDAI - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan VIVS|Aclarion, Inc. (ACON) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Akoya Biosciences, Inc.|THMO (ThermoGenesis Holdings Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Talis Biomedical Corp TLIS|Rasio rega marang prakiraan pendapatan T2 Biosystems, Inc. (TTOO)